Skip to main content
OpenTrials
Completed

NCT Number: NCT02400632

MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions

The purpose of this study is to demonstrate the efficacy of MagicTouch DCB in reducing late lumen loss / suppressing neointimal tissue formation as assessed by Quantitative Coronary Angiography / Intravascular Ultrasound examination for the treatment of coronary artery lesions ranging from 3.0 mm to 3.5 mm of diameter and lesion length ≤ 15 mm.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital Bandeirantes, São Paulo, Brazil

Loading trial locations.

About this study

Prospective, multicenter, randomized study designed to enroll 60 subjects with In-stent Restenosis, To demonstrate the efficacy of MagicTouch Drug-Coated Balloon in reducing late lumen loss / suppressing neointimal tissue formation as assessed by Quantitative Coronary Angiography / Intravascular Ultrasound examination for the treatment of coronary artery lesions ranging from 3.0 mm to 3.5 mm of diameter and lesion length ≤ 15 mm.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must be ≥18 and ≤ 80 years of age
  • Symptomatic ischemic heart disease;
  • Acceptable candidate for Coronary Artery Bypass Graft (CABG) or Angioplasty;
  • Target lesion located in a native coronary artery
  • Target lesion (maximum length is 15 mm by visual estimate) covered by a single balloon;
  • Reference vessel diameter must be ≥3.0 to ≤ 3.5 mm by visual estimate;
  • Target lesion ≥50% and <100% stenosed by visual estimate
  • Restenosis of initially stented main vessel.

Exclusion criteria

  • Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure;
  • Patient has had a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure;
  • Lesions in bypass grafts or bifurcations
  • Any non-target vessel or lesion intended to be treated during the index procedure, which is an unprotected left main, ostial lesion, chronic total occlusion (CTO), heavily calcified, bifurcation, vein grafts, have angiographic evidence of thrombus, be anything requiring atherectomy, thrombectomy, or pre-treatment with anything other than balloon angioplasty;
  • Patient presents with cardiogenic shock;
  • Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion
  • Unprotected left main coronary artery disease with ≥50% stenosis;
  • Totally occluded target vessel (TIMI flow 0);
  • Calcified target lesion(s) which cannot be successfully pre-dilated;
  • A significant (>50%) stenosis proximal or distal to the target lesion that cannot be covered by same single balloon
  • Diffuse distal disease to target lesion with impaired runoff;
  • Left ventricular ejection fraction (LVEF) ≤30% (LVEF must be obtained within 1 months prior to the index procedure).

Treatment and study plan

MAGIC-TOUCH Drug-eluting Balloon

Device

in-stent restenosis treated with drug eluting balloon

Primary outcomes

  1. Efficacy assessed by the percentage (%) of in-stent neointimal tissue formation evaluated by Intravascular Ultrasound (IVUS)

    Time frame: 6-months after procedure

Secondary outcomes

  1. Safety assessed by the composite rate for major adverse cardiac events at 12 months. (MACE: cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) and Target vessel revascularization (TVR)

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Scitech Produtos Medicos SA

Industry

Registry information

Official study title

Assessment of the Novel MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions

Acronym: MAGIC-TOUCH

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Mar 27, 2015
Registry last updated
Mar 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.